Skip to content
Screener

Incyte INCY Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$0-100%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$300K-80.0%
AbbVie logo
AbbVieABBV

Segments

By segment

See full
Reportable Segment$2.5M-89.0%

Other financials

Income statement

See full
Revenue$1.7B+37.7%
Gross profit$1.6B+38.0%
Operating income$697.9M+31.6%
Net income$585.6M+44.6%
EPS (diluted)$2.81+37.7%

Balance sheet

See full
Cash & equivalents$4.0B+104%
Total debt$38.3M-9.8%
Total equity$6.3B+52.1%
Total assets$7.9B+35.2%

Cash flow

See full
Operating cash flow$507.7M+1,035%
CapEx$1.6M-43.5%
Free cash flow$509.3M+1,069%

Valuation

See full
Market cap$24.44B+58.0%
Enterprise value$20.49B+51.2%
P/E15.2×-2.6×
P/S4.2×+0.8×

Profitability

See full
Gross margin92.6%-0.3pp
Operating margin30.6%+4.8pp
Net margin27.7%+8.7pp
FCF margin34%+12.3pp

Returns & leverage

See full
Return on equity30.7%+6.4pp
Debt / equity0.0×
Current ratio4.6×+1.7×

Where this comes from

Reported directly by Incyte in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The source filing: Incyte’s 10-Q, filed July 28, 2026.

Filed
Jul 28, 2026, 4:02 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000879169-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development516,950494,9171,032,853932,196
Selling, general and administrative351,735331,022679,822656,713
Asset impairment and related disposal costs23,214
Loss on change in fair value of acquisition-related contingent consideration2,49922,7612,33134,333
Total costs, expenses and other976,141685,2151,947,7001,532,945
Income from operations697,898530,314999,015735,482
Interest income38,11825,13671,80548,065
Interest expense(582)(594)(1,151)(1,254)

Item 1. Financial Statements

FAQ

What is Incyte's contingent consideration fair value adjustments?
Incyte (INCY) reported contingent consideration fair value adjustments of $2.5M in Q2 2026.
How has Incyte's contingent consideration fair value adjustments changed year-over-year?
Incyte's contingent consideration fair value adjustments decreased by 89.0% year-over-year, from $22.76M to $2.5M.
What is the long-term trend for Incyte's contingent consideration fair value adjustments?
Over 3 years (2021 to 2025), Incyte's contingent consideration fair value adjustments has grown at a -25.4% compound annual growth rate (CAGR), from $14.74M to -$6.13M.

Ask your AI about Incyte's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude